Skip to main content
. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933

Fig. 6.

Fig. 6

A. Title: Cardiovascular death or HF hospitalizations/urgent visits in the subgroup of HF with preserved ejection fraction. Legend: In the subgroup of HF with preserved ejection fraction, there was a 25% relative risk reduction in the composite endpoint of cardiovascular death or HF hospitalizations/urgent visits among those treated with SGLT2 inhibitors compared with placebo (OR 0•75; 95% CI 0•62–0•91). B. Title: Cardiovascular death or HF hospitalizations/urgent visits in the subgroup of HF with reduced ejection fraction. Legend: In the subgroup of HF with reduced ejection fraction, there was a 25% relative risk reduction in the composite endpoint of cardiovascular death or HF hospitalizations/urgent visits among those treated with SGLT2 inhibitors compared with placebo (OR 0•75; 95% CI 0•69–0•81).